CN108379568A - A kind of phylaxin polypeptide vaccine and its application in treating breast cancer - Google Patents
A kind of phylaxin polypeptide vaccine and its application in treating breast cancer Download PDFInfo
- Publication number
- CN108379568A CN108379568A CN201810227306.9A CN201810227306A CN108379568A CN 108379568 A CN108379568 A CN 108379568A CN 201810227306 A CN201810227306 A CN 201810227306A CN 108379568 A CN108379568 A CN 108379568A
- Authority
- CN
- China
- Prior art keywords
- resistin
- mouse
- phylaxin
- vaccine
- breast cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kind of phylaxin polypeptide vaccine and its applications in treating breast cancer, belong to biotechnology.The polypeptide vaccine of the present invention is made of Resistin albumen specific polypeptides sections with immunologic adjuvant, becomes Resistin polypeptide vaccines.The vaccine can activate body lymphocyte, and generate the immune neutralizing antibody for Resistin albumen by multiple subcutaneous injections.Resistin polypeptide vaccines have no effect on the tolerance of body sugar and level of insulin resistance.Resistin polypeptide vaccines can significantly inhibit the growth of ER positive breast tumors and three negative breast tumors under mouse model, in addition, Resistin polypeptide vaccines can significantly inhibit the growth of mouse ER positive breast tumors and three negative breast tumors under the obese model that high fat diet induces.The present invention provides new approach to improve the therapy of current breast cancer.
Description
Technical field
The present invention relates to a kind of phylaxin polypeptide vaccine and its applications in treating breast cancer, belong to biotechnology neck
Domain.
Background technology
Breast cancer is the significant problem of the global women's health of puzzlement, and there are about 1,400,000 people to be diagnosed as mammary gland in the annual whole world
Cancer, and about 500,000 people die of the disease, breast cancer is first cause of death of 40-55 Sui women.The year of China's breast cancer
Equal growth rate is 3%-4%, becomes the fastest-rising cancer of the death rate in city, especially with Shanghai, Beijing, Tianjin and coastal
Area is the hotspot of China's breast cancer, has accounted for the first place of female malignant incidence.
It is fat closely related with the morbidity of breast cancer caused by unreasonable and inherent cause of dietary structure etc..One side
Face, Long-term High-fat fat diet frequently result in serum estrogen level and increase extremely, and then promote the development of breast cancer.On the other hand,
Excess fat tissue provides energy for proliferation and the migration of tumour cell, at the same adipose tissue be also tumour cell transfer and
Chemotherapy exhaust protects place.
Recently, more and more reports focus on the Adipocyte Factor promotion breast cancer origin of adipose tissue secretion, i.e. mammary gland
The proliferation and Cells Proliferation of Human Breast Cancer of cancer stem cell and transfer, for example, Leptin, Adiponectin, interleukin family,
Resistin etc..
Resistin protein (Resistin) is generated and is secreted by adipocyte in mouse, in human body mainly by fatty thin
Born of the same parents and mononuclear macrophage generate and secretion.Resistin be reported it is closely related with fat and type-II diabetes, clinically,
Resistin levels are proportionate with breast cancer patients grade malignancy in serum, and Resistin can promote in vitro culture breast cancer thin
The migration of born of the same parents, while experiment in vitro proves, Resistin promotes the proliferation of breast carcinoma stem cell and the chemotherapy of breast cancer is promoted to support
It is anti-.
Based on this, the function of Resistin is checked in vivo or is expected to effectively treat under breast cancer, especially obese model
Breast cancer treatment.But there has been no the treatment breast cancer schemes of effective targeting Resistin at present.
The therapeutic scheme clinically of breast cancer includes that operation cuts off primary lesion, regional lymph nodes Radical dissection, and hormone is controlled
Treatment and chemicotherapy etc..However, the recurrence rate and the death rate of breast cancer are still very high, and along with higher cost and give
The pain and burden larger with patient.
The prior art has developed gene vaccine for treating tumor-related illness, i.e. carrier construction expresses certain antigen
Genetic fragment, using the plasmid direct immunization animal, antigen fragment expresses in host and body is stimulated to generate immune answer
It answers and inhibits tumor cell proliferation, transfer or direct killing tumour cell.But gene vaccine be related to gene in specific tissue or
The intake of organ and expression problem.
Invention content
The object of the present invention is to provide a kind of inhibition tumours, the especially polypeptide vaccine of breast cancer cell growth.The present invention
Mouse directly is immunized by immunological method in the specific peptide fragment of Resistin, stimulation mouse body generates immune response, stimulation
The immune neutralizing antibody of the anti-Resistin albumen of lymphocytic emiocytosis reaches inhibition tumour by checking Resistin protein functions
The purpose of cell growth.The specific peptide fragment of Resistin provided by the invention can be used for preparing the ER positives and triple negative breast cancer life
Long inhibitor.
Polypeptide vaccine of the present invention is made of Resistin albumen specific polypeptides sections with immunologic adjuvant, described
Resistin albumen specific polypeptides sections include that (mouse source Resistin full length sequences are from N-terminal by polypeptide sequence EAIDKKIKQDF
30-40 amino acids).
Polypeptide vaccine of the present invention, is subcutaneously injected into Mice Body, and antigen presenting cell is passed through in Mice Body
Make by T lymphocytes the immune neutralizing antibody that anti-Resistin albumen is largely generated in Mice Body after identifying and handling.
On the other hand, vaccine of the invention, which can be used for preparing, inhibits tumour growth medicament, in particular for breast cancer and fertilizer
The treatment of tumor of breast under fat model.Mouse can significantly inhibit E0771 after inoculation Resistin polypeptide vaccines in advance
(C57BL/6 background mices；ER positive breast cancers) and 4T1 (BALB/c background mices；Triple negative breast cancer) breast cancer is primary
The growth at position, further, under the obese model of high fat diet induction, Resistin polypeptide vaccines are for E0771 and 4T1
Breast cancer is more notable in the growth inhibition effect of original site.
In conclusion immune Resistin polypeptide vaccines are subcutaneously injected the present invention provides a kind of, and detect its inhibition
The effect of growth of breast cancers.The vaccine, which can stimulate, to be generated in a large amount of functional anti-Resistin protein immunizations and is resisted in Mice Body
Body.Moreover, after advance inoculation, under different background mouse, it is swollen to significantly inhibit ER positive breasts for Resistin polypeptide vaccines
The growth of tumor and three negative breast tumors；Meanwhile Resistin polypeptide vaccines have no effect on the tolerance of body sugar and insulin resistant
Level has the effect of the growth of breast cancers under obese model more obvious.Therefore, above-mentioned immunotherapy can be to improve
The therapy of breast cancer provides new thinking and approach at present.
Description of the drawings
The N.S occurred in attached drawing of the present invention indicates that no conspicuousness, * indicate P<0.05, * * indicates P<0.01, * * * indicate P
<0.001。
Fig. 1 show the monomer structure (a) of Resistin albumen, tripolymer (b), six dimeric structure figures (c) and
The full length sequence information (d) of Resistin.Wherein arrow is signified and red marks (1#) to be selected for needed for vaccine preparation
Peptide fragment.
Fig. 2 is shown:The inoculation of Resistin polypeptide vaccines and subsequent experimental flow chart.Female mice is carried out 12 weeks high
5 weeks standard mouse antibody was subcutaneously injected toward every mouse web portion at the 12nd, 14,15,16,17,20,22 week in fat Diet-Induced Obesity
Prepare adjuvant (Beijing Bo Aolong Immune Technology Corp.) and antigen peptide fragment mixed liquor (1:1,50 μ g), every note of control mice
5 weeks standard murine antibodies are penetrated for adjuvant and bovine serum albumin (BSA) mixed liquor (1:1,50 μ g).
After vaccine has been injected in Fig. 3 displays, at the 17th week, normal diet is verified by Western Blot and high fat diet is small
Recognition capability of the antibody generated in serum in mouse body for Resistin in the 3T3-L1 adipocytes of differentiation and maturation.It is positive right
According to for commercially with anti-Resistin antibody (PEPROTECH companies), negative control is that normal diet mouse injects control treatment
Serum.
Fig. 4 shows that produced antibody is for Resistin's in ELISA verification normal diets and high fat diet mice serum
Identification and binding ability.Positive control is commercially with anti-Resistin antibody (PEPROTECH companies), and negative control is mouse IgG.
Fig. 5 is by collected mice serum by Protein G purifying.Antibody after purification and mature fat cell supernatant
After liquid is incubated incubation 6h in advance, tumour cell E0771 is handled.The change of downstream signaling pathway is detected by Western Blot.
Fig. 6 the 18th week to C57BL/6 normal diets and high fat diet control mice group and give vaccine group carry out glucose
Resistance to tested person (GTT).
Fig. 7 the 19th week to C57BL/6 normal diets and high fat diet control mice group and give vaccine group carry out insulin
Resistance to tested person (ITT).
Fig. 8 shows that C57BL/6 normally gives with high fat diet mouse and compares (BSA) processing or vaccine processing and E0771
(the second mammary fat pad injects 5*10 for cell transplantation5Cell) flow chart and corresponding mouse weight variation.
Fig. 9 C57BL/6 are normal/obesity mice under the conditions of giving control or vaccine, the measurement figure of mouse tumor volume
(a) typical figure (b) is shone with mouse systemic.
After Figure 10 slaughters C57BL/6 mouse, measure normally with given under the conditions of obesity compare or vaccine under the conditions of it is small
Mammary tumors weight chart (b), the audio-visual picture (a) with each grouping tumor size.
Serum moderate resistance Resistin exempted from after Figure 11 ELISA measurings normal diets and high fat diet mouse inject vaccine
Epidemic disease neutralizing antibody concentration (using PEPROTECH companies produce anti-Resistin antibody as positive control and using its concentration as
Standard calculates antibody concentration in serum；To inject the normal diet mice serum of BSA as negative control).It is small gained will to be measured
Mouse antibody concentration in serum does map analysis with mammary gland of mouse tumor weight, and calculates correlation coefficient r value between the two.
Figure 12 BALB/c are normal/obesity mice under the conditions of giving control or vaccine, the measurement figure of mouse tumor volume.
After Figure 13 slaughters BALB/c mouse, measure normally with given under the conditions of obesity compare or vaccine under the conditions of mouse
Tumor of breast weight chart (b), the audio-visual picture (a) with each grouping tumor size.
Serum moderate resistance Resistin exempted from after Figure 14 ELISA measurings normal diets and high fat diet mouse inject vaccine
Epidemic disease neutralizing antibody concentration (using PEPROTECH companies produce anti-Resistin antibody as positive control and using its concentration as
Standard calculates antibody concentration in serum；To inject the normal diet mice serum of BSA as negative control).It is small gained will to be measured
Mouse antibody concentration in serum does correlogram analysis with mammary gland of mouse tumor weight, and calculates correlation coefficient r value between the two.
Specific implementation mode
Unless specifically stated otherwise, C57BL/6 and BALB/c female mices used in following embodiment structure obese model are the after birth
Surrounding starts to feed high lipid food 12 weeks until fat, and high lipid food fat ratio is 60%.
Unless specifically stated otherwise, reagent used in following embodiment and material are to analyze the reagent of pure rank, and can be from
The commercially available synthesis of regular channel or purchase, wherein Purity needed for immune mouse is>=95%.
The present invention is by control group and vaccinates a group group progress statistical analysis, P<0.05 indicates that group difference has system
Meter learns meaning.
After polypeptide vaccine is immune, the method for anti-Resistin neutralizing antibodies effect in mouse blood is for present invention detection
Identification and combination of the antibody generated by Western Blot and ELISA detections for antigen；Existed by immune neutralization experiment
Inhibiting effect of the antibody produced by vitro detection for Resistin functions.
The detection of the preparation and immune neutralizing antibody of 1 Resistin protein vaccines of embodiment
In Mice Body, Resistin is mainly secreted by mature fat cell, and in vivo mainly with tripolymer and six
Dimer form exists.First, have using B cell antigen epi-position forecast analysis software analysis Resistin protein sequences and exempt from more by force
Then the stronger region of gained antigenicity is predicted using protein three-dimensional structure analysis software, according to egg in the region of epidemic focus
It is chosen the location of in white matter monomer and polymer 3D structures and is exposed to albumen 3D body structure surfaces and the stronger sequence of antigenicity
Row synthesis small peptide simultaneously carries out subsequent experimental assessment.
With 1# polypeptides (N-terminal α spirals, sequence EAIDKKIKQDF) as antigen, while passing through cysteine idol in its C-terminal
Join BSA, facilitates antigen presentation, enhancing immune.The antigen polypeptide of synthesis is diluted to 1mg/ml concentration with physiological saline solution.
Resistin polypeptide vaccines by 5 weeks standard murine antibodies for adjuvant (Beijing Bo Aolong Immune Technology Corp.) with
Antigen mixed liquor (volume ratio 1:1) it forms.
According to the experimental program of Fig. 2, female mice (C57BL/6 or BALB/c backgrounds) is first subjected to normal diet or high in fat
Diets 12 weeks.Vaccine (100 μ L), control was subcutaneously injected toward every mouse web portion at the 12nd, 14,15,16,17,20,22 week
Mouse 5 weeks standard murine antibodies of every injection are for adjuvant and bovine serum albumin (BSA) mixed liquor (1:1,100 μ L).
At the 17th week, about 100 μ L are taken a blood sample in ep pipes by orbital sinus, are stored at room temperature after twenty minutes, in 4 DEG C of centrifugations
3500 revs/min of machine centrifuges 15 minutes, Aspirate supernatant (serum).With primary antibody dilution with 1:500 dilution proportion mice serums,
It is tested using protein immunoblotting, verifies the antibody generated in serum for Resistin albumen in 3T3-L1 adipocytes
(serum for injecting control treatment using normal diet mouse is produced anti-recognition reaction as negative control with PEPROTECH companies
Resistin antibody is positive control).Experimental result is shown in the normal and high fat diet mice serum after having injected vaccine
All produce the identification Resistin (Fig. 3) that Resistin antibody can be specific.
Further, by ELISA experiment detection vaccinate after mice serum for Resistin albumen identification with
Binding ability.If Fig. 4 is shown, 1 is being carried out:50、1:100、1:200、1:Under 400 gradient dilution, mice serum can be strongly
It identifies and the Resistin albumen under unified with nature state (it is right for feminine gender to inject the serum of control treatment with normal diet mouse
According to dilution ratio is same as above；Using the anti-Resistin antibody of PEPROTECH companies production as positive control, dilution ratio 1：
200、1：400、1：800、1：1600).
After detecting and vaccinating, whether Serum Antibody can check the function of Resistin albumen.By remaining serum
About 40 μ L-50 μ L are purified dimly and with Protein G beads with PBS, elution, obtain antibody after purification.It will resist
Body is according to 1:50 ratio is incubated at room temperature 6h with 3T3-L1 mature fat cells supernatant (serum-free), then newborn with 37 DEG C of cultures
Adenocarcinoma cell E07711h.Cell is received, Western blot are carried out.Experimental result such as Fig. 5 shows, the mouse blood after vaccinating
Phosphorylation activations of the Resistin for AKT in tumour cell and S6 in antibody energy significantly suppression of cell supernatant obtained by pureization
(having reported that Resistin can promote AKT and S6 phosphorylations), the antibody for illustrating after purification can check the biology work(of Resistin
Energy.The serum purifying gained of control treatment is injected as negative control with normal diet mouse；With the anti-of PEPROTECH companies production
Resistin antibody is positive control, dilution ratio 1：100.
2 Resistin polypeptide vaccines of embodiment effectively inhibit C57BL/6 mouse and BALB/c mouse normal diet and high in fat
Breast tumor growth under Diet-Induced Obesity model
After normal diet and Diet-Induced Obesity mouse are carried out 5 vaccines hypodermic injections.Epidemic disease is detected by blood sugar test paper
Seedling influences mouse blood sugar level.Mouse sugar tolerance level and level of insulin resistance are detected respectively, as shown in Figures 6 and 7, injection
Mouse sugar is resistant to vaccine or level of insulin resistance does not influence.Meanwhile to the change of weight in the entire experiment flow of mouse
Change record display, mouse weight, which is not exposed to vaccine injection, influences (Fig. 8).
After carrying out 6 times that vaccine is subcutaneously injected, injected toward C57BL/6 the second mammary fat pads of right side of mice at the 21st week
E0771 breast cancer cells 5*105A (ER positive cell lines；Cell is resuspended in 100 μ l PBS buffer solution).Injecting mammary gland
Occur touching visible tumor of breast the 6th day after cancer cell E0771, in mammary fat pad, carried out last time again in the 7th day
Vaccine injection.Using the major diameter (cm) and minor axis (cm) of tumour produced by every mouse of vernier caliper measurement, and utilize formula meter
Calculate gross tumor volume.Gross tumor volume (cm3)=0.5* major diameter (cm) * minor axis (cm)2.From the 6th day, continuous 8 days daily same
One time, the major diameter and minor axis of tumour are measured, and calculate the volume size of tumour, and done figure and compare.As shown in figure 9,
After the injection of Resistin polypeptide vaccines, mouse mammary tumor growth is obviously suppressed；In addition, in fat group mouse, injection
After after the injection of Resistin polypeptide vaccines, mouse mammary tumor volume reduces more obvious.
Further, mouse was slaughtered in the 13rd day in measurement, takes out mouse tumor tissue and weigh, and take pictures, such as Figure 10.It is real
Test the results show that Resistin polypeptide vaccines injection after, mouse mammary tumor weight saving；In addition, in fat group mouse, note
After penetrating after the injection of Resistin polypeptide vaccines, mouse mammary tumor weight reduces more obvious.
After ELISA measuring normal diet groups give the injection of Resistin polypeptide vaccines, mouse mammary tumor weight subtracts
Gently；In addition, for fat group mouse, after injection Resistin polypeptide vaccines injection, mouse mammary tumor weight saving is brighter
It is aobvious.Further, it measures normal diet and high fat diet mouse injected the immune neutralizing antibodies of serum moderate resistance Resistin after vaccine
Concentration, and it is mapped with tumor weight, such as Figure 11, experimental result is shown, either in normal diet group still in height
Fat diet group, Resistin antibody concentrations and tumor weight are in inverse ratio (r=0.69 in normal diet in serum；R in high fat diet
=0.80), illustrate inhibiting effect of the immune neutralizing antibody generated in Mice Body to tumor of breast.
In order to verify under different mouse backgrounds, under the conditions of the transplanting of different mouse source cells system, Resistin polypeptide vaccines are
It is no that there is same purpose.We carry out same above-mentioned vaccine injection operation, then, the second breast of turning right on BALB/c mouse
Gland fat pad injects 4T1 breast cancer cells 2*106A (three negative cells systems；Cell is resuspended in 100 μ l PBS buffer solution).It is right
Mouse mammary tumor carries out cubing (Figure 12) and weight is weighed and Resistin antibody is dense in take pictures (Figure 13) and serum
The ELISA of degree is measured and the relational graph (Figure 14) with tumor weight.Experimental result is consistent with C57BL/6 mouse, i.e. Resistin
After polypeptide vaccine injection, mouse mammary tumor volume reduces, weight saving；In fat group mouse, mouse mammary tumor body is noted
Product and weight reduce more obvious.Resistin antibody concentrations and tumor weight are in inverse ratio (normal diet in mice serum simultaneously
Middle r=0.44；R=0.61 in high fat diet).
Although the present invention has been described by way of example and in terms of the preferred embodiments, it is not limited to the present invention, any to be familiar with this skill
The people of art can do various change and modification, therefore the protection model of the present invention without departing from the spirit and scope of the present invention
Enclosing be subject to what claims were defined.
SEQUENCE LISTING
<110>Military medical research institute of PLA Academy of Military Sciences
<120>A kind of phylaxin polypeptide vaccine and its application in treating breast cancer
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 11
<212> PRT
<213>Mouse
<400> 1
Glu Ala Ile Asp Lys Lys Ile Lys Gln Asp Phe
1 5 10
Claims (9)
1. a kind of phylaxin subunit vaccine, which is characterized in that including Resistin albumen specific polypeptides sections, the Resistin
Albumen specific polypeptides section includes amino acid sequence such as SEQ ID NO：Polypeptide shown in 1.
2. a kind of phylaxin subunit vaccine according to claim 1, which is characterized in that further include immunologic adjuvant.
3. a kind of phylaxin subunit vaccine according to claim 1 or 2, which is characterized in that the Resistin albumen
The amino acid sequence of specific polypeptides section such as SEQ ID NO：Shown in 1.
4. according to a kind of any phylaxin subunit vaccine of claims 1 to 3, which is characterized in that the Resistin
The C-terminal of albumen specific polypeptides section is coupled bovine serum albumin by cysteine.
5. a kind of phylaxin subunit vaccine according to any one of claims 1 to 4, which is characterized in that be polypeptide vaccine.
6. a kind of any phylaxin subunit vaccine of Claims 1 to 5 is in preparing breast tumor growth inhibitor
Using.
7. application according to claim 6, which is characterized in that the tumor of breast include fat induction tumor of breast,
The ER positives and triple negative breast cancer.
8. a kind of any phylaxin subunit vaccine of Claims 1 to 5 is being developed or is being prepared for treating breast cancer
Application in drug.
9. a kind of carrier bacterin, which is characterized in that it includes SEQ ID NO to carry coding：More peptide or proteins including sequence shown in 1
The nucleotide of matter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810227306.9A CN108379568B (en) | 2018-03-20 | 2018-03-20 | Polypeptide vaccine of resistin and application thereof in treating breast cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810227306.9A CN108379568B (en) | 2018-03-20 | 2018-03-20 | Polypeptide vaccine of resistin and application thereof in treating breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108379568A true CN108379568A (en) | 2018-08-10 |
| CN108379568B CN108379568B (en) | 2020-05-08 |
Family
ID=63067750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810227306.9A Active CN108379568B (en) | 2018-03-20 | 2018-03-20 | Polypeptide vaccine of resistin and application thereof in treating breast cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108379568B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107550932A (en) * | 2017-08-22 | 2018-01-09 | 中国医科大学 | A kind of method for judging tumor susceptibility mouse model |
| RU2679625C1 (en) * | 2018-11-08 | 2019-02-12 | Ильясов Шамиль Сионович | 3-o-sulfamoiloxy-6-oxa-7β-methyl-d-homo-8α-estra-1,3,5(10)-trien-17α-one application for the breast cancer treatment, including the triple negative form, and its production method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015688A (en) * | 2001-01-19 | 2007-08-15 | 赛托斯生物技术公司 | Molecular antigen array |
-
2018
- 2018-03-20 CN CN201810227306.9A patent/CN108379568B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015688A (en) * | 2001-01-19 | 2007-08-15 | 赛托斯生物技术公司 | Molecular antigen array |
Non-Patent Citations (2)
| Title |
|---|
| BING PAN等: "Inhibitory effects of resistin-13-peptide on the proliferation, adhesion, and invasion of MDA-MB-231 in human breast carcinoma cells", 《ENDOCRINE-RELATED CANCER》 * |
| 陈瑜等: "小鼠resistin基因慢病毒表达载体构建及在KMB17细胞中的表达", 《生物技术》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107550932A (en) * | 2017-08-22 | 2018-01-09 | 中国医科大学 | A kind of method for judging tumor susceptibility mouse model |
| RU2679625C1 (en) * | 2018-11-08 | 2019-02-12 | Ильясов Шамиль Сионович | 3-o-sulfamoiloxy-6-oxa-7β-methyl-d-homo-8α-estra-1,3,5(10)-trien-17α-one application for the breast cancer treatment, including the triple negative form, and its production method |
| WO2020096485A1 (en) * | 2018-11-08 | 2020-05-14 | Шамиль Сионович ИЛЬЯСОВ | Treatment for breast cancer, including triple-negative breast cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108379568B (en) | 2020-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gonzalez et al. | A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial | |
| KR102079921B1 (en) | Vaccine for the prevention of breast cancer relapse | |
| CN103648513B (en) | Yeast-Brachyury (Brachyury) immunotherapeutic composition | |
| CN101072875B (en) | Novel cancer antigen peptide and the use thereof | |
| CN108495649A (en) | The new epiposition vaccine of therapeutic anti-cancer | |
| CN108379568A (en) | A kind of phylaxin polypeptide vaccine and its application in treating breast cancer | |
| Lembcke et al. | Development of immunologic assays to measure response in horses vaccinated with xenogeneic plasmid DNA encoding human tyrosinase | |
| CN105175527A (en) | Heat shock protein complex for breast cancer specificity and application of complex | |
| CN104853764B (en) | For preventing and treating the MSI- specificity frameshit peptides (FSP) of cancer | |
| Shakibapour et al. | Anti-cancer immunoprotective effects of immunization with hydatid cyst wall antigens in a non-immunogenic and metastatic triple-negative murine mammary carcinoma model | |
| JP2017043635A (en) | Composition and method for treating cancer | |
| Zhang et al. | Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy | |
| CN112812158A (en) | Polypeptide fragment C and application thereof | |
| CN107073087A (en) | Treat therapeutic a variety of peptide T specific immunotherapies of metastatic encephaloma | |
| KLEINBERG et al. | Studies on human α-lactalbumin: Radioimmunoassay measurements in normal human breast and breast cancer | |
| Talwar | Making of a vaccine preventing pregnancy without impairment of ovulation and derangement of menstrual regularity and bleeding profiles | |
| CN108484768A (en) | Neutralizing antibody and the application in treating breast cancer is immunized in a kind of anti-phylaxin | |
| CN105142662B (en) | IDH1 R132H mutation positive cancer treatments or the means and method of diagnosis | |
| CN102212505A (en) | Immune killer cell, preparation method thereof, medicinal composition containing immune killer cell and set | |
| CN115282143A (en) | Application of alpha-mangostin in preparation of medicine for treating melanoma and medicine | |
| CN102250206A (en) | New HLA-A2 restrictive epitope polypeptide and application thereof | |
| CN102250208A (en) | New HLA-A2 restrictive epitope polypeptide and application thereof | |
| CN115837067A (en) | Application of spleen aminopeptide in preparation of medicine for improving intestinal flora condition | |
| CN110804088A (en) | Cytomegalovirus-associated antigen short peptide and application thereof | |
| CN104211796A (en) | Compound formed by pancreas cancer related peptide and heat shock protein and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |